ENZN — Enzon Pharmaceuticals Cashflow Statement
0.000.00%
- $11.13m
- -$34.86m
- 68
- 54
- 43
- 55
Annual cashflow statement for Enzon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.979 | -1.31 | -0.469 | -0.186 | 1.37 |
Deferred Taxes | |||||
Changes in Working Capital | 7.88 | 0.931 | -0.032 | -0.271 | 0.089 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | 6.91 | -0.38 | -0.501 | -0.659 | 1.3 |
Financing Cash Flow Items | — | -0.524 | 0 | — | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | -7.96 | 43.1 | 0 | — | -1.27 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.05 | 42.7 | -0.501 | -0.659 | 0.03 |